Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
Eunice S WangAaron D GoldbergMartin TallmanRoland Bruno WalterChatchada KaranesKaramjeet SandhuCarlos Enrique VigilRobert H CollinsVinay JainRichard M StonePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.
Keyphrases
- newly diagnosed
- acute myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- locally advanced
- prognostic factors
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- squamous cell carcinoma
- acute lymphoblastic leukemia
- wild type
- radiation therapy
- patient reported outcomes
- patient reported